Stocks Tumble On Tetraphase, Flexion Failures; Surge On Akebia Win
This article was originally published in Scrip
Antibiotic developer Tetraphase Pharmaceuticals Inc. and arthritis pain drug maker Flexion Therapeutics Inc. were battered in after-hours trading on Sept. 8 after the companies said their lead drug candidates failed to reach statistical significance in late-stage clinical trials, but investors rewarded Akebia Therapeutics Inc. for positive mid-stage results for its anemia drug after the stock market closed.
You may also be interested in...
Tetraphase has been keeping its head down since a 2015 Phase III trial failure for its lead antibiotic drug eravacycline sliced around $1.3bn from the company's market cap – but 2017 will be a turnaround year, says CEO Guy Macdonald.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.